title: [Clarifying some concepts and clinical significance of refractory or recurrent neovascular age-related macular degeneration].
abstract: Anti-VEGF therapy is currently one of the main treatments for neovascular age-related macular degeneration (nAMD). Clinically, patients under standardized anti-VEGF therapy showed different responses, of which recurrences or even insensitivity were found in some patients. However, the specific definitions of these various clinical responses are still unclarified. Therefore, to consolidate and define these concepts are of great importance regarding to future efficacy comparison, treatment response clarification and novel drug switching therapies.
authors: Department of Ophthalmology, Affiliated First People's Hospital , Shanghai Jiaotong University, Shanghai 200080, China.
authors: Jingke
authors: J
authors: Zhao
authors: Department of Ophthalmology, Affiliated First People's Hospital , Shanghai Jiaotong University, Shanghai 200080, China; Email: xdsun@sjtu.edu.cn.
authors: Xiaodong
authors: X
authors: Sun
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D012008:Recurrence; D055502:Secondary Prevention; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A